Sales of drugs for atrial fibrillation are projected to grow from $790 million in 2008 to $6.1 billion by 2018

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.594, 2010-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antiarrhythmic drugs for atrial fibrillation

By Marinelli Alessandro Capucci Alessandro

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 8, 2011-06 ,pp. : 1201-1215

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic Boost for Atrial Fibrillation Market: Three New Class III Drugs Set to Triple Sales

By Adis International Limited

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 8, 2006-01 ,pp. : 11-14

Adis International

Access to resources Recommend Favorite

Non-Antiarrhythmic Drugs to Prevent Atrial Fibrillation

By Moro Concepción Hernández-Madrid Antonio Matía Roberto

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 3, 2010-06 ,pp. : 165-173

Adis International

Access to resources Recommend Favorite

Retail pharmacy drug sales reached $US429 billion in 13 major markets in the 12 months to April 2008

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 558, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Oral antiarrhythmic drugs in converting recent onset atrial fibrillation

By Deneer Vera H.M. Borgh Marieke B.I. Kingma J. Herre Lie-A-Huen Loraine Brouwers Jacobus R.B.J.

Pharmacy World and Science, Vol. 26, Iss. 2, 2004-04 ,pp. : 66-78

Springer Publishing Company

Access to resources Recommend Favorite